GAMMA Investing’s Monopar Therapeutics MNPR Stock Holding History

GAMMA Investing’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.31K	Sell	25 -4	-14%	-$248	﹤0.01%	3700
2026 Q1	$1.59K	Buy	29 +15	+107%	+$906	﹤0.01%	3732
2025 Q4	$914	Buy	14 +3	+27%	+$245	﹤0.01%	3813
2025 Q3	$898	Buy	+11	New	+$492	﹤0.01%	3633

Other funds holding MNPR

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing's MNPR Position: Q2 2026 in Review

GAMMA Investing reduced its Monopar Therapeutics (MNPR) stake by 14% in Q2 2026, selling an estimated $248 and leaving 25 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3700.

GAMMA Investing first reported a position in MNPR in Q3 2025 and has held it in 4 quarters since. 3 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

GAMMA Investing held 25 shares of Monopar Therapeutics worth $2.31K as of Q2 2026.
GAMMA Investing sold 4 Monopar Therapeutics shares in Q2 2026, an estimated $248.
Monopar Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3700 holding.
GAMMA Investing first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 4 quarters since.
3 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.